文献速递核素与放射性配体治疗肿瘤 PET/CT

弥漫性大B细胞淋巴瘤骨骼与脾脏病变对[177Lu]Lu-DOTA-利妥昔单抗的肿瘤病灶摄取

Tumor Lesion Uptake of [ 177 Lu]Lu-DOTA-Rituximab in Skeletal and Splenic Disease in Diffuse Large B-Cell Lymphoma.
PubMed 文献 · Clin Nucl Med · 2025-01-29

本文报道一例弥漫性大B细胞淋巴瘤(DLBCL)患者,FDG PET/CT显示广泛骨骼及脾脏结外病变。探索基于[177Lu]Lu-DOTA-利妥昔单抗的放射免疫治疗,研究其在CD20阳性淋巴瘤中的生物分布与剂量测定,观察到骨骼和脾脏病灶中示踪剂浓度异常高。

要点

  • DLBCL患者FDG PET/CT显示广泛骨骼及脾脏结外病变,提示不良预后。
  • [177Lu]Lu-DOTA-利妥昔单抗在骨骼和脾脏病灶中示踪剂浓度异常高。
  • 结果支持未来将放射免疫治疗用于复发难治性DLBCL患者。

核心结论

  • 观察到[177Lu]Lu-DOTA-利妥昔单抗在骨骼和脾脏病灶中示踪剂浓度异常高,支持其未来用于复发难治性DLBCL患者的潜在放射免疫治疗应用。

研究设计与样本

  • 本文为病例报告,报道一例DLBCL患者,FDG PET/CT显示广泛骨骼及脾脏结外病变。
  • 探索基于[177Lu]Lu-DOTA-利妥昔单抗的放射免疫治疗,研究其在CD20阳性淋巴瘤中的生物分布与剂量测定。

主要发现

  • [177Lu]Lu-DOTA-利妥昔单抗在骨骼和脾脏病灶中示踪剂浓度异常高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, and a sizable fraction of the DLBCL patients presents with advanced, relapsed, and refractory disease, demonstrating poor response to standard chemotherapy regimens. Radioimmunotherapy (RIT) has shown to be clinically effective in refractory DLBCL. We present the case of a patient with DLBCL with [ 18 F]FDG-avid widespread skeletal as well as splenic involvement as poor prognostic extranodal disease on FDG PET/CT. RIT based on [ 177 Lu]Lu-DOTA-rituximab was explored to study the biodistribution and dosimetry of [ 177 Lu]Lu-DOTA-rituximab in CD20-positive lymphoma. An exceptionally high tracer concentration in skeletal and splenic disease was observed, supporting its potential RIT application in relapsed and refractory DLBCL patients in the future.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Edamadaka Y, Parghane RV, Basu S, et al. Tumor Lesion Uptake of [ 177 Lu]Lu-DOTA-Rituximab in Skeletal and Splenic Disease in Diffuse Large B-Cell Lymphoma. Clin Nucl Med. 2025. PMID: 39876085. doi:10.1097/RLU.0000000000005695

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。